Despite well-documented racial and ethnic disparities in breast cancer treatment,6,12,32 our findings show a narrowing of disparities in the receipt of ERBB2-targeted therapies over time among Medicare beneficiaries with ERBB2-positive breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.